DUBLIN, September 23, 2021--(BUSINESS WIRE)--The "Advanced Renal Cell Carcinoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Advanced Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Renal cell carcinoma is the most common type of kidney cancer. It usually starts as a tumor in one of your kidneys. And like other cancers, it can spread to other parts of your body. That's when doctors call it metastatic. As the tumor grows, it spreads into fat or major blood vessels around the kidney. It may also creep into the adrenal gland, which sits right on top of the organ. Kidney cancer most often spreads to the lungs and bones, but it can also go to the brain, liver, ovaries, and testicles. The process used to find out if cancer has spread within the kidney or to other parts of the body is called staging. The information gathered from the staging process determines the stage of the disease. It is important to know the stage in order to plan treatment. The following tests and procedures may be used in the staging process: CT scan; MRI (magnetic resonance imaging); Chest x-ray; and bone scan. Different types of treatments are available for patients with renal cell cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials.
The report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Renal Cell Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Renal Cell Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Renal Cell Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Renal Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Renal Cell Carcinoma.
Major Players in Advanced Renal Cell Carcinoma
There are approx. 40+ key companies which are developing the therapies for Advanced Renal Cell Carcinoma. The companies which have their Advanced Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Roche.
This report covers around 40+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Advanced Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Advanced Renal Cell Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Renal Cell Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Renal Cell Carcinoma drugs.
Advanced Renal Cell Carcinoma Report Insights
Advanced Renal Cell Carcinoma Pipeline Analysis
Impact of Drugs
Advanced Renal Cell Carcinoma Report Assessment
Pipeline Product Profiles
Inactive drugs assessment
Daiichi Sankyo, Inc.
Eli Lilly and Company
Jiangsu HengRui Medicine Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Peloton Therapeutics, Inc.
CRISPR Therapeutics AG
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/42gns2
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005398/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900